Belépés

NCT07536022Toboroz

At-home taVNS for Neurorehabilitation in Parkinson's Disease

Developing At-home taVNS for Neurorehabilitation in Parkinson's Disease

Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. jún. 15.

Rövid összefoglaló (regiszter, angolul)

The goal of this clinical trial is to learn if taVNS works to treat symptoms of Parkinson's Disease in adults. It will also learn about the feasibility and preliminary efficacy of taVNS administered at home by the participant. The main questions it aims to answer are: 1. Is at-home taVNS feasible and effective for treating symptoms of Parkinson's Disease? How often are participants completing the stimulation protocol? What are the side effects of stimulation experienced by participants? How do participants rate the experience of taVNS sessions at home? How do participants' scores on assessments and questionnaires change with taVNS treatments? 2. How does taVNS impact connections between neural networks in the brain of patients with Parkinson's Disease at rest? Participants will: * Have a baseline MRI scan to take images of their brain. * Complete a series of assessments and questionnaires to evaluate their Parkinson's Disease motor symptoms, cognitive and neuropsychiatric symptoms, and other non-motor symptoms. * Have an initial taVNS session where their threshold to perceive the stimulation will be measured. This value will be used to stimulate each participant at a specific dose relative to their individual perception of stimulation. * Be trained on how to use the taVNS device and system and have one 1-hour taVNS session where their vitals will be monitored. * Self-administer 1-hour daily taVNS sessions for 8 weeks at-home, complete tolerability questionnaires, and weekly remote check-ins with study staff. * After 4-weeks of at-home taVNS, participants will come in-person to repeat the questionnaires and assessments from the first visit. * Following the 8 weeks of taVNS sessions, participants will repeat the MRI scan, assessments and questionnaires from visit 1. * Participants will complete questionnaires remotely 1 month following their last taVNS sessions.

Állapot (regiszter)
Toboroz
Vizsgálattípus
Beavatkozással járó
Résztvevők száma
16 (tervezett)
Első benyújtás
2026. ápr. 2.
Kezdés
2026. jún. 1.
Elsődleges befejezés
2027. jún.
Fő szponzor
Medical University of South Carolina
Betegségek
Parkinson-kór
NCT-szám
NCT07536022

Mit vállalsz

  • Vizsgálat típusa: Beavatkozással járó
  • Tervezett résztvevők: 16
  • 2026. jún. 1. és az elsődleges befejezés (2027. jún.) között
  • 1 helyszín, 1 országban
  • Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket

A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.

Ki nem vehet részt

Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.

Korábbi kezelés

  • Visual hallucinations or other psychotic symptoms, other than mild visual hallucinations secondary to PD medications, not requiring treatment, or well controlled on stable doses of quetiapine or pimavenserin.
  • Use of B-Blockers, dopamine blocking agent (other than quetiapine or pimavenserin in stable doses), antiarrhythmic medication, acetylcholine esterase inhibitor (study doctor will consider if on stable doses), midodrine, fludrocortisone, droxidopa, or anticholinergic drugs

Más betegség

  • A history of taVNS in the last 6 months
  • A history of brain surgery, traumatic brain injury or stroke
  • Diagnosis of a nervous system disorder besides PD, alcohol or substance use disorder, or unstable cardiovascular conditions
  • History of myocardial infarction or arrhythmia, bradycardia
  • A history of other significant gait impairment unrelated to PD (e.g. orthopedic deformities)
  • Failure to meet all criteria on a standardized MRI/taVNS safety screening: This includes, but is not limited to, the presence of claustrophobia, implanted electronic devices that are not 3T MRI compatible (e.g., pacemakers), metallic objects or fragments (e.g., bullets), and non-removable hair clips or piercings.
  • Individuals with a diagnosis of cognitive impairment (MoCA \< 24) that would make them unable to understand and follow study instructions or to consent for themselves.
  • Individuals with a history of seizure(s)

Egyéb

  • Inability to complete gait/ motor assessments (without assistance or assistance devices)
  • Ear trauma, facial pain, anatomical abnormalities or other barriers preventing earpiece fit
  • Pregnancy
  • Inability to perform at-home taVNS procedures safely and properly (either alone or with the aid of a caregiver)
  • Uncorrected visual or hearing impairments that would impact performance on cognitive tests or ability to follow study procedures

Kiket keres a vizsgálat

  • Issues with walking, balance, and gait as determined by a movement disorders neurologist (a score of equal to or greater than 1 on MDS-UPDRS items 2.12 (walking and balance), and 3.10 (gait))
  • Diagnosis of idiopathic Parkinson's Disease based on UK Brain Bank diagnostic criteria
  • Hoehn and Yahr Stage 2-4 as determined by a movement disorders neurologist
  • Stable on dopaminergic medications over the past 30 days prior to enrollment in the study

Életkor a regiszterben: 40 év – 85 év · Nem: nők és férfiak · Egészséges önkénteseket nem fogad

A teljes feltétellista: ClinicalTrials.gov

Helyszínek (1)

Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.

HelyszínVárosOrszágHelyszín állapota
Medical University of South Carolina
Ennek a helyszínnek vagy a koordinátora? Erősítsd meg az állapotát
CharlestonEgyesült ÁllamokToboroz

Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.